Skip to Content

Caladrius Biosciences, Inc.

Merger

  • Date:
  • 5/2/2022
  • Company Name:
  • Caladrius Biosciencesd, Inc.
  • Stock Symbol:
  • CLBS
  • Company Name - Buyer:
  • Cend Therapeutics, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 4/27/2022

Case Finder

Locate any case using the tools below.

NEW YORK, May 2, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Caladrius Biosciences, Inc. (NASDAQ: CLBS) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Cend Therapeutics, Inc.

On April 27, 2022, Caladrius announced that it had entered into an agreement to merge with Cend in a deal which values each company at approximately $90 million.  Pursuant to the merger agreement, at the close of the merger Cend stockholders will receive approximately 60.5 million shares of Caladrius common stock, subject to certain closing conditions, resulting in the stockholders of each company owning approximately 50% of the combined company.  The deal is scheduled to close in third quarter of 2022.

Bragar Eagel & Squire is concerned that Caladrius’ board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Caladrius’ stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Caladrius Biosciencesd. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: